Autonomix Medical, Inc. announced on April 16, 2025, that the European Patent Office (EPO) granted Patent No. 3,226,792, titled 'Systems And Methods For Regulating Organ and/or Tumor Growth Rates, Function, and/or Development.' This patent relates to neuromodulation and covers methods and systems used in nerve and receptor monitoring, electrophysiological monitoring, and surgical procedures.
The granted patent specifically covers systems and mechanisms that regulate prostate and tumor growth, including methods to sense, ablate, and verify neurological traffic to and from the prostate and lower urinary tract organs. This aims to slow, halt, or reverse the growth of a prostate gland or tumor.
CEO Brad Hauser emphasized that this European patent further validates the broad applicability of their technology across multiple conditions and anatomical targets. While the company's primary focus is on pancreatic cancer pain, this patent supports future applications and expansion opportunities in various peripheral nerve bundles associated with pain and other conditions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.